AKTX — Akari Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Akari Therapeutics' Preclinical Data Demonstrates The Potential Of Its Novel ADC Spliceosome Modulating Payload, Ph1
Brief: Akari Therapeutics PLC Enters Ordinary Share Purchase Agreement With White Lion Capital
Akari Therapeutics PLC expected to post a loss of 11 cents a share - Earnings Preview
Brief: Akari Therapeutics PLC Files For Mixed Shelf Of Up To $75 Million – SEC Filing
Brief: Akari Therapeutics Cash On Hand Expected To Be Sufficient To Fund Planned Operations Into September 2025
Brief: Akari Therapeutics Announces $7.6 Million Private Placement Offering
Brief: Akari Therapeutics Announces Key Leadership Appointments
Brief: Akari Therapeutics Regains Full Nasdaq Compliance
Brief: Akari Therapeutics Announces Shareholder Approval In Connection With Peak Bio Merger
Brief: Akari Therapeutics Receives Positive and Constructive Pre-IND Feedback from US FDA for PAS-nomacopan in Treatment of Geographic Atrophy
Brief: Charles Steve Theofilos Files To Report Stake Of 9.99% In Akari Therapeutics PLC As Of May 31, 2024 - SEC Filing
Brief: Akari Therapeutics Secures $7.6 Million in Upsized Financing Round
U.S. STOCKS ON THE MOVE-Salesforce, Birkenstock, Kohls Corp
Brief: Akari Therapeutics PLC On May 1 Began To Implement A Reduction-In-Force Of Approximately 67% Of Its Total Workforce
Brief: Samir Patel Appointed Interim CEO For Akari Therapeutics
Brief: Akari Therapeutics And Peak Bio Announce Portfolio Prioritization Plan For Combined Go-Forward Merger Entity
Brief: Akari Therapeutics Agrees To Sell And Issue In A Private Placement Approximately $1.6 Million ADSS
Brief: Akari Therapeutics Appoints Experienced Life Sciences Entrepreneur Samir R. Patel, M.D. To Board Of Directors
Brief: Akari Therapeutics Files Prospectus Relates To Resale, By Selling Shareholders, Of Upto Total Of 642,753 ADS, Representing 1.3 Billion Ordinary Shares